Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biora Therapeutics

Explore full profile

Clinical laboratory services to provide physicians and patients with accurate, timely and state-of-the-art test results

San Diego, United StatesFounded 2010Biotech & Life Sciences
Valuation $37M Market cap · 2026
Revenue $4K Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding

About Biora Therapeutics

Biora Therapeutics is a biotechnology company focused on revolutionizing the delivery of therapeutics. The company specializes in developing innovative smart pill technologies designed for targeted drug delivery to the gastrointestinal (GI) tract and systemic, needle-free delivery of large molecules. These advancements aim to replace traditional injection methods, offering a more convenient and less invasive option for patients managing chronic diseases. Biora Therapeutics serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and patients seeking advanced therapeutic solutions. Operating in the biopharmaceutical market, the company leverages its proprietary technologies, such as NaviCap, BioJet, and GITrac, to create value. Biora's business model involves the development and commercialization of these smart pill technologies, generating revenue through product sales, licensing agreements, and potential partnerships with larger pharmaceutical firms. The company is currently in the investigational stage, with its products limited to investigational use by Federal law.

Source: Dealroom company data

At a glance

Founded
2010
Headquarters
San Diego, United States
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning Biora Therapeutics.

See all news

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Athyrium Capital Management

Series B and later2 investors entered at this stage

  • Highbridge Capital Management
  • Davidson Kempner Capital Management
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96.8%
🇮🇪 Ireland3.2%
2 countries shown
Web traffic by country
1.7K monthly visits
across markets
🇺🇸 United States94.1%
🇮🇳 India5.9%
Top 2 markets shown

Patents

Estimated portfolio value
$61M

44 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Biora Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biora Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.